Health Canada has authorized a new drug to treat postpartum depression.

The regulator says z uranolone, a pill sold under the brand name Zurzuvae, is authorized in Canada to relieve symptoms of moderate or severe depression after childbirth.

"This is the first drug authorized in Canada for this purpose," Health Canada said in a statement to CBC News on Tuesday.

The medication is recommended for moderate to severe postpartum depression, with severity measured by the level of impairment in daily functioning.

Biogen, the drug's developer, says zuranolone is to be taken once a day for 14 days and will be available in Canada early in 2026, but governments and insurers would still need to d etermine coverage.

Health Canada said in an email it has done a "thorough review" of Biogen's

See Full Page